Have a feature idea you'd love to see implemented?
Let us know!
NWBO Northwest Biotherapeutics Inc
Price (delayed)
$0.28
Market cap
$349.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.08
Enterprise value
$402.2M
Highlights
Northwest Biotherapeutics's quick ratio has increased by 25% from the previous quarter and by 25% YoY
The company's gross profit rose by 23% QoQ but it fell by 13% YoY
Northwest Biotherapeutics's revenue has increased by 23% QoQ but it has decreased by 13% YoY
NWBO's debt has soared by 81% YoY and by 13% QoQ
The equity has contracted by 25% YoY and by 4.4% from the previous quarter
Key stats
What are the main financial stats of NWBO
Market
Valuations
Earnings
Shares outstanding
1.25B
Market cap
$349.51M
Enterprise value
$402.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
206.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
244.5
Revenue
$1.65M
EBIT
-$67.57M
EBITDA
-$65.64M
Free cash flow
-$61.1M
Per share
Balance sheet
Liquidity
EPS
-$0.08
Free cash flow per share
-$0.05
Book value per share
-$0.06
Revenue per share
$0
TBVPS
$0.02
Total assets
$28.23M
Total liabilities
$85.97M
Debt
$55.57M
Equity
-$76.5M
Working capital
-$51.2M
Debt to equity
-0.73
Current ratio
0.09
Quick ratio
0.05
Net debt/EBITDA
-0.8
Margins
Efficiency
Dividend
EBITDA margin
-3,990.2%
Gross margin
100%
Net margin
-4,479%
Operating margin
-3,779.6%
Return on assets
-260.2%
Return on equity
N/A
Return on invested capital
-388.9%
Return on capital employed
N/A
Return on sales
-4,107.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NWBO stock price
How has the Northwest Biotherapeutics stock price performed over time
Intraday
1.45%
1 week
-5.47%
1 month
-17.4%
1 year
-58.21%
YTD
-60.06%
QTD
-12.5%
Financial performance
How have Northwest Biotherapeutics's revenue and profit performed over time
Revenue
$1.65M
Gross profit
$1.65M
Operating income
-$62.18M
Net income
-$73.68M
Gross margin
100%
Net margin
-4,479%
The company's gross profit rose by 23% QoQ but it fell by 13% YoY
Northwest Biotherapeutics's revenue has increased by 23% QoQ but it has decreased by 13% YoY
NWBO's operating margin is down by 18% year-on-year but it is up by 13% since the previous quarter
NWBO's net margin is up by 15% QoQ and by 2.2% YoY
Growth
What is Northwest Biotherapeutics's growth rate over time
Valuation
What is Northwest Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
206.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
244.5
The EPS has contracted by 14% from the previous quarter and by 14% YoY
The equity has contracted by 25% YoY and by 4.4% from the previous quarter
The P/S is 59% below the 5-year quarterly average of 501.5 and 51% below the last 4 quarters average of 419.7
Northwest Biotherapeutics's revenue has increased by 23% QoQ but it has decreased by 13% YoY
Efficiency
How efficient is Northwest Biotherapeutics business performance
The ROS has grown by 15% from the previous quarter and by 4.7% YoY
The return on assets rose by 8% year-on-year but it has declined by 4.8% since the previous quarter
The ROIC has increased by 6% QoQ
Dividends
What is NWBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NWBO.
Financial health
How did Northwest Biotherapeutics financials performed over time
The total assets is 67% smaller than the total liabilities
NWBO's total liabilities is up by 34% year-on-year and by 4.8% since the previous quarter
The current ratio has declined by 25% year-on-year but it is up by 13% since the previous quarter
NWBO's debt is 173% higher than its equity
NWBO's debt has soared by 81% YoY and by 13% QoQ
Northwest Biotherapeutics's debt to equity has decreased by 46% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.